Comparing ARIA‐E severity scales and effects of treatment management thresholds
Gregory Klein(Roche (Switzerland)), Derk D. Purcell(BioClinica (United States)), Marco Lyons(Roche (United Kingdom)), Paul Delmar(Roche (Switzerland)), Szofia Bullain(Roche (Switzerland)), Luc Bracoud(BioClinica (United States)), Jakub Wojtowicz(Roche (Switzerland)), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Jerome Barakos(Sutter Health), Jochen B. Fiebach(Pathodiagnostik Berlin), Joyce Suhy(BioClinica (United States)), Marzia A. Scelsi(Roche (United Kingdom))
Cited by 12
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k